A JAK2 inhibitor; inhibits autophosphorylation of recombinant JAK2 at 30 and 100 μM; decreases levels of phosphorylated JAK2

SD-1029 – 1 mg

Brand:
Cayman
CAS:
118372-34-2
Storage:
-20
UN-No:
Non-Hazardous - /

SD-1029 is a Janus kinase 2 (JAK2) inhibitor.{48790,48791} It inhibits autophosphorylation of recombinant JAK2 when used at concentrations of 30 and 100 μM and decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and paclitaxel-resistant OVCAR8TR cells when used at a concentration of 10 μM.{48790} SD-1029 (10 μM) decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells.{48790} It decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells when used at a concentration of 10 μM.{48792} SD-1029 (100 and 1,000 nM) inhibits hepatitis A virus replication in GL37 cells.{48791}  

 

Out of stock

Add to quotes
SKU: 21029 - Category:

Description

A JAK2 inhibitor; inhibits autophosphorylation of recombinant JAK2 at 30 and 100 μM; decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and OVCAR8TR cells at 10 μM; decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells at 10 μM; decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells at 10 μM; inhibits hepatitis A virus replication in GL37 cells at 100 and 1,000 nM

Formal name: 9-(3,4-dichlorophenyl)-2,7-bis[(dimethylamino)methyl]-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione, dihydrobromide

Synonyms:  JAK2 Inhibitor III|Janus-Associated Kinase 2 Inhibitor III

Molecular weight: 639.3

CAS: 118372-34-2

Purity: ≥80% (mixture of isomers)

Formulation: A solid

Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|JAK/STAT Signaling||Research Area|Cancer|Transcription Factors|STATs||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Hepatitis

Related products

  • A zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers

    1,2-Dipalmitoyl-sn-glycero-3-PC – 250 mg

    1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}  

     

    Brand:
    Cayman
    SKU:10009473 - 250 mg

    Available on backorder

    Add to quotes
    View product page
  • CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}

    CAY10512 – 500 mg

    The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}  

     

    Brand:
    Cayman
    SKU:10009536 - 500 mg

    Available on backorder

    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 500 µg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 500 µg

    Available on backorder

    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 10 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 10 mg

    Available on backorder

    Add to quotes
    View product page